ABVC BioPharma Entered Into A Term Sheet To License Global Rights Of CNS Drugs With The Indications Of MDD And ADHD To AiBtl BioPharma At The Valuation Of $667M
Portfolio Pulse from Benzinga Newsdesk
ABVC BioPharma has entered into a term sheet to license global rights of its CNS drugs for MDD and ADHD to AiBtl BioPharma, with a valuation of $667M. The agreement includes AiBtl stock of 46 million shares (57% of AiBtl) and milestone cash payments of $7M with royalties of 5% of net sales, up to $200 million, after the product's launch. AiBtl plans to go IPO and get listed on NASDAQ in 2024.
October 26, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ABVC BioPharma's licensing deal with AiBtl BioPharma could provide significant revenue through milestone payments and royalties. The company's focus on CNS drugs for MDD and ADHD, markets expected to grow significantly, could also boost its prospects.
The licensing deal with AiBtl BioPharma could provide ABVC BioPharma with significant revenue through milestone payments and royalties. Additionally, the company's focus on CNS drugs for MDD and ADHD, markets that are expected to grow significantly in the coming years, could boost its prospects.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100